Parameters of coagulant and fibrinolytic capacity and activity in postmenopausal women: Within-subject variability

Thrombosis Research

Volumn 107, Issue 5, 2002, Pages 229-233

  Horne III, McDonald K ^a,b   McCloskey, Donna Jo ^a   Cullinane, Ann M ^a   Merryman, Paula K ^a   Rick, Margaret E ^a   Hortin, Glen L ^a   Waclawiw, Myron A ^a   Cannon III, Richard O ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Hyperhomocysteinemia; Postmenopause; Statistics; Thrombophilia

Indexed keywords

ANTITHROMBIN; C REACTIVE PROTEIN; FIBRINOGEN; FOLLITROPIN; HOMOCYSTEINE; PROTEIN C; PROTEIN S; PROTHROMBIN; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5 LEIDEN;

ARTICLE; BLOOD ANALYSIS; BLOOD CLOTTING; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LONGITUDINAL STUDY; PARTIAL THROMBOPLASTIN TIME; POSTMENOPAUSE; PRIORITY JOURNAL; SCREENING; BLOOD; HYPERHOMOCYSTEINEMIA; REPRODUCIBILITY;

BIOLOGICAL MARKERS; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; FACTOR V; FEMALE; FIBRINOLYSIS; HUMANS; HYPERHOMOCYSTEINEMIA; LONGITUDINAL STUDIES; POSTMENOPAUSE; REPRODUCIBILITY OF RESULTS;

EID: 0036762154     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(02)00332-8     Document Type: Article

References (29)

1. Daly E., Vessey M.P., Hawkins M.M., Carson J.L., Gough P., Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet. 348:1996;977-980.
2. Jick H., Derby L.E., Myers M.W., Vasilakis C., Newton K.M. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet. 348:1996;981-983.
3. Grodstein F., Stampfer M.J., Goldhaber S.Z., Manson J.E., Golditz G.A., Speizer F.E.et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet. 348:1996;983-987.
4. Gutthann S.P., Rodriguez L.A.G., Castellsague J., Oliart A. Hormone replacement therapy and risk of venous thromboembolism: population based case-cohort study. Br. Med. J. 314:1997;796-800.
5. Varas-Lorenzo C., Garcia-Rodriguez L.A., Cattaruzzi C., Troncon M.G., Agostinis L., Perez-Gutthann S. Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: a population-based study in southern Europe. Am. J. Epidemiol. 147:1998;387-390.
6. Grady D., Wenger N.K., Herrington D., Khan S., Furberg C., Hunninghake D.et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. Ann. Intern. Med. 132:2000;689-696.
7. Boschetti C., Cortellaro M., Nencioni T., Bertolli V., Volpe A.D., Zanussi C. Short- and long-term effects of hormone replacement therapy (transdermal estradiol vs. oral conjugated equine estrogens, combined with medroxyhyprogesterone acetate) on blood coagulation factors in postmenopausal women. Thromb. Res. 62:1991;1-8.
8. Caine Y.G., Bauer K.A., Barzegar S., ten Cate H., Sacks F.M., Walsh B.W.et al. Coagulation activation following estrogen administration to postmenopausal women. Thromb. Haemost. 68:1992;392-395.
9. Gilabert J., Estelles A., Cano A., Espana F., Barrachina R., Grancha S.et al. The effect of estrogen replacement therapy with or without progestogen on the fibrinolytic system and coagulation inhibitors in postmenopausal status. Am. J. Obstet. Gynecol. 173:1995;1849-1854.
10. Scarabin P.-Y., Alhenc-Gelas M., Plu-Bureau G., Taisne P., Agher R., Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. Arterioscler. Thromb. Vasc. Biol. 17:1997;3071-3078.
11. Koh K.K., Mincemoyer R., Bui M., Csako G., Pucino F., Guetta V.et al. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N. Engl. J. Med. 336:1997;683-690.
12. Bonduki C.E., Lourenco D.M., Baracat E., Haidar M., Noguti M.A.E., da Motta E.L.A.et al. Effect of estrogen-progestin hormonal replacement therapy on plasma antithrombin III of postmenopausal women. Acta Obstet. Gynecol. Scand. 77:1998;330-333.
13. Teede H.J., McGrath B.P., Smolich J.J., Malan E., Kotsopoulos D., Liang Y.-L.et al. Postmenopausal hormone replacement therapy increases coagulation activity and fibrinolysis. Arterioscler. Thromb. Vasc. Biol. 20:2000;1404-1409.
14. Walker I.D. Factor V Leiden: should all women be screened prior to commencing the contraceptive pill? Blood Rev. 13:1999;8-13.
15. Greaves M., Baglin T. Laboratory testing for heritable thrombophilia: impact of clinical management of thrombotic disease. Br. J. Haematol. 109:2000;699-703.
16. Seligsohn U., Lubetsky A. Genetic susceptibility to venous thrombosis. N. Engl. J. Med. 344:2001;1222-1231.
17. Fraser C.G., Harris E.K. Generation and application of data on biological variation in clinical chemistry. Crit. Rev. Clin. Lab. Sci. 27:1989;409-437.
18. Thompson S.G., Martin J.C., Meade T.W. Sources of variability in coagulation factor assays. Thromb. Haemost. 58:1987;1073-1077.
19. Blomback M., Eneroth P., Landgren B.M., Lagerstrom M., Anderson O. On the intraindividual and gender variability of haemostatic components. Thromb. Haemost. 67:1992;70-75.
20. Chambless L.E., McMahon R., Wu K., Folsom A., Finch A., Shen Y.-L. Short-term intraindividual variability in hemostasis factors. The ARIC study. Ann. Epidemiol. 2:1992;723-733.
21. Rosenson R.S., Tangney C.C., Hafner J.M. Intraindividual variability of fibrinogen levels and cardiovascular risk profile. Arterioscler. Thromb. 14:1994;1928-1932.
22. Nguyen N.D., Ghaddar H., Stinson V., Chambless L.E., Wu K.K. ARIC hemostasis study: IV. Intraindividual variability and reliability of hemostatic factors. Thromb. Haemost. 73:1995;256-260.
23. De Maat M.P.M., de Bart A.C.W., Hennis B.C., Meijer P., Havelaar A.C., Mulder P.G.H.et al. Interindividual and intraindividual variability in plasma fibrinogen, TPA antigen, PAI activity, and CRP in healthy, young volunteers and patients with angina pectoris. Thromb. Vasc. Biol. 16:1996;1156-1162.
24. Salomaa V., Rasi V., Stengard J., Vahtera E., Pekkanen J., Vartiainen E.et al. Intra- and interindividual variability of hemostatic factors and traditional cardiovascular risk factors in a three-year follow-up. Thromb. Haemost. 79:1998;969-974.
25. Sakkinen P.A., Macy E.M., Callas P.W., Cornell E.S., Hayes T.E., Kuller L.H.et al. Analytical and biologic variability in measurements of hemostasis, fibrinolysis, and inflammation: assessment and implications for epidemiology. Am. J. Epidemiol. 149:1999;261-267.
26. Verhoef P. Hyperhomocysteinemia and risk of vascular disease in women. Semin. Thromb. Hemost. 26:2000;325-334.
27. Sullivan P., Csako G.A., Hortin G.L. Dual analysis of homocysteine and cysteine. Clin. Chem. 47:2001;A62.
28. Horne M.K., Merryman P.K., Cullinane A.M. Histidine-proline-rich glycoprotein binding to platelets mediated by transition metals. Thromb. Haemost. 85:2001;890-895.
29. Young D.S., Harris E.K., Cotlove E. Biological and analytic components of variation in long-term studies of serum constituents in normal subjects. Clin. Chem. 17:1971;403-410.